Cavrotolimod Plus PD-1 Blockers Showing Efficacy in Advanced Cancers, Trial Reports
News
The investigational therapy cavrotolimod (AST-008), in combination with the PD-1 inhibitor Keytruda (pembrolizumab), was safe and well-tolerated, and showed signs of efficacy in people with advanced solid tumors who failed ... Read more